VESSELPLASTY™, a revolutionary treatment designed by Jerry Lin, the Chairman of A-Spine Holding Group Corp., to treat VCF (Vertebral Compression Fracture) occurred in the millions of aging population suffering from osteoporosis and tumor, provides the distinctive advantages of controlling the volume of the void and the potential risk of bone filler material leakage during treatment procedure. The leakage of filler materials, mostly PMMA bone cement, during traditional vertebroplasty procedure poses major risks to the patients the complications of which include spinal cord compression, incontinence and paralysis. VESSELPLASTY™ employs a non-stretchable PET (Polyethelene Terephthlate) fabric as a container of the filler material for VCF treatment. The potential risks can be reduced significantly. This proprietary innovation from ASH is secured by over 10 patents worldwide. More patents are pending.

“This is the first international congress where VESSELPLASTY™ will be introduced to the attending physicians from different countries, and we are quite confident of the acceptance of VESSELPLASTY™ by the spine professionals.” Jerry Lin said. “Those who perform vertebroplasty and Kyphoplasty in their regular practice will immediately recognize the significance and will adopt VESSELPLASTY™ without explanation. The product speaks for itself!” He added.

A-SPINE HOLDING GROUP CORP., based in Taipei, Taiwan is an innovative company dedicated to the development, design, manufacturing, and marketing of clinically significant spine products.

For further information, please contact:

Jack Sung, Manager of International Marketing Dept

Tel: +886-2-26272977 Ext. 120

Fax: +886-2-66065955

VCF patient receiving VESSELPLASTY™ can be discharged on the same day

Web:www.aspine.net

VCF patient receiving VESSELPLASTY™ can be discharged on the same day

Courtesy by Dr. Bambang Darwono